Tagrisso 80mg tablets are for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive (NSCLC) which have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy, as determined by an approved test.
$
Follow Tagrisso 80mg tablets
of funded
Contribute
of funded
Supporters